SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 598.92 |
| Enterprise Value ($M) | n/a |
| Book Value ($M) | 376.53 |
| Book Value / Share | 1.68 |
| Price / Book | n/a |
| NCAV ($M) | 71.27 |
| NCAV / Share | 0.32 |
| Price / NCAV | n/a |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.67 |
| Return on Assets (ROA) | -0.33 |
| Return on Equity (ROE) | -0.46 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 2.28 |
| Current Ratio | 2.29 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 251.57 |
| Assets | 556.84 |
| Liabilities | 180.30 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Ra Capital Management, L.p. | 1.20 | ||
| 13G/A | Glaxosmithkline Plc | 7.40 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 204,073 | 1,079,548 | 18.90 | |
| 129,487 | 639,732 | 20.24 | |
| 104,231 | 687,436 | 15.16 | |
| 77,172 | 487,311 | 15.84 | |
| 202,479 | 625,593 | 32.37 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| CRSP – CRISPR Therapeutics AG | CRVS – Corvus Pharmaceuticals, Inc. |
| CURR – CURRENC Group Inc. | EOLS – Evolus, Inc. |
| ESPR – Esperion Therapeutics, Inc. |
Financial data and stock pages provided by
Fintel.io